Clinical Trial · NCT06234319

CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma

Overview

This project intends to evaluate the role of C-X-C chemokine receptor type 4 (CXCR4) targeted PET/MRI integrated imaging in the grading and molecular typing of brain gliomas, using primary glioma patients as the research subjects and post-operative histopathological analysis as the reference, and to establish an evaluation model for the prognosis of primary glioma patients.

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Contacts

Du ZHenwei, Ph.D (CONTACT)

peter11dzw@126.com

+8618580503880

Chen Xiao, Ph.D (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06234319

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

CXCR4

Ligand Class: Small Molecules

Chelator: HBED-CC

Eligibility

Inclusion

Participate in CXCR4 PET/MRI imaging within 15 days before surgery;
The patient voluntarily participates and signs the informed consent form.
Surgical resection of glioma lesion tissue can be used for pathological analysis;
The patient is at least 18 years old;
1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria;

Exclusion

Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.
1. Pregnant or breastfeeding patients;
Molecular typing was not determined by histologic examination;
patients with claustrophobia;
The image quality of the imaging is poor and cannot be used for diagnosis and evaluation;